New combo drug CagriSema shows promise in curbing appetite and food intake
NCT ID NCT06207877
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This completed phase 1 trial tested whether CagriSema, a combination of two drugs (cagrilintide and semaglutide), can reduce how much people with overweight or obesity eat, curb their appetite, and slow stomach emptying. 62 participants received either CagriSema or a placebo for about 32 weeks. The study measured changes in energy intake during meals and other appetite-related outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Parexel International GmbH
Berlin, 14050, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If it works, this could point toward a more effective weight-loss treatment that helps people eat less and feel fuller.
What could go wrong
This is a small, early-phase study (62 people) that only measures short-term effects on appetite and stomach emptying. It may not lead to a marketable treatment, and side effects from the drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.